Lymphedema Prevention Strategies

Recruiting in Palo Alto (17 mi)

Overseen bySimona F. Shaitelman

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This research study is to learn about breast cancer patients' opinions about screening for lymphedema (a side effect of breast cancer treatment in which the arm can become heavy, painful, and/or swollen) and their satisfaction with the lymphedema screening program.

Research Team

Simona F. Shaitelman

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

The PREVENT trial is for English-speaking breast cancer patients who've had axillary lymph node dissection. It includes those with preoperative measurements (Cohort I) and those within 0-6 months post-surgery intending to continue follow-up at MD Anderson (Cohort II). Patients unable to complete a questionnaire are excluded.

Inclusion Criteria

Patients who participate in Cohort A will be eligible for enrollment in Cohort

I had surgery to remove lymph nodes due to breast cancer and visited the Nellie B. Connally Breast Center about a year later.

I had breast cancer surgery with lymph node removal and plan to follow up at MD Anderson within 6 months.

See 2 more

Exclusion Criteria

Inability to complete a self-administered questionnaire

Treatment Details

Interventions

PREVENT: PeRomEter Visualization to ENd Treatment-related Lymphedema (Behavioural Intervention)

Trial OverviewThis study evaluates patient opinions on lymphedema screening, which detects swelling after breast cancer treatment. Cohort I receives annual screenings, while Cohort II has more intensive follow-ups. Patient satisfaction with the program is also assessed.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: Cohort II (patients followed intensively for lymphedema)Experimental Treatment1 Intervention

We will prospectively follow a cohort of 279 patients who have recently undergone ALND in this upcoming year with intensive lymphedema screening.

Group II: Cohort I (patients receiving annual lymphedema screening)Experimental Treatment1 Intervention

We will retrospectively retrieve information on patients who previously underwent preoperative perometer lymphedema screening during the past year who were treated definitively for their breast cancer with an ALND, and for whom no follow-up postoperative lymphedema screening was done.